Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection

NCT04444245 is registered in ClinicalTrials.gov with Black Tie Medical, Inc. as lead sponsor.

NCT NCT04444245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection
Lead sponsor
Black Tie Medical, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 15, 2022
Completion date
August 15, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone disturbance, ovarian failure, perimenopausal disorder